How has your week started, myeloma world?

We hope it's going well so far.

We once again have a rather long list of new myeloma research we'd like to discuss with you. We sus­pect most of our readers will find at least one or two studies in the report to be of particular interest.

We begin today's report with a discussion of a somewhat rare eye-related side effect of Velcade (bor­tez­o­mib) and a possible way to control the …

We tried, myeloma world, but we couldn't come up with a short title for today's report.

There were just too many words needed to describe the three research articles that we plan to review with you in this edition of Myeloma Morning.

First, we have an important new study out of Spain that in­ves­ti­gates the sig­nif­i­cance of Bence Jones protein in smol­der­ing multiple myeloma patients.

Next, we turn to a study by researchers in Japan. They in­ves­ti­gate different methods for measuring …

A happy Saturday to you, myeloma world.

We hope your weekend has gotten off to an excellent start.

Today's edition of Myeloma Morning focuses primarily on a study that was included in yesterday's list of new myeloma-related research. The study summarizes trends in allogeneic (donor) stem cell transplantation in Europe over the last two decades.

Although the study focuses on European trends, we believe it should be of interest to Beacon readers regardless where they may be. With the global …

We're very glad to see you again, myeloma world.

Myeloma Morning was on brief hiatus while we helped with the Beacon's article about the recently published Ninlaro (ixazomib) clinical trial results.

Now that the Ninlaro article has been published, however, it's time to get back to normal Myeloma Morning business.

And there's a lot of it. In fact, there are almost 20 items in the list of new myeloma research at …

A happy Tuesday to you, myeloma world.

We have some in­ter­est­ing re­search to share with you.

First, we have re­­sults of a Phase 2 study investi­gating Empliciti (elotuzu­mab) in com­bi­na­tion with Velcade (bor­tez­o­mib) and dexa­metha­sone (Decadron) in re­lapsed and re­frac­tory myeloma patients. The re­­sults show that Empliciti plus Velcade and dexa­metha­sone im­proves pro­gres­sion-free sur­vival com­pared to Velcade and dexa­metha­sone alone, without adding any sig­nif­i­cant side effects.

We also report on a study out of Italy that explores using

Good day, myeloma world.

Monday's tend to be quiet here at Myeloma Morning Headquarters – at least when it comes to new research that needs to be reviewed and summarized. Today is no exception. There was no new myeloma-related research when we checked this morning, and just one or two news items.

We do have a few things, however, that we'd like to review with you.

First, we mentioned last week that this month's issue of the Journal of …

Hello again, myeloma world.

As we continue catching up after the recent onslaught of new myeloma-related research, we're pleased to report that it's a sunny spring day outside. More importantly, our top story today reflects Mother Nature's pleasant disposition.

In particular, there is updated data about multiple myeloma survival in the United States, and it's good news.

It's just an annual update – a single new value for survival five-years from the time of diagnosis. And it's for patients diagnosed …